OKUR (OnKure Therapeutics) EPS (Basic) : $-3.90 (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics EPS (Basic)?

OnKure Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-1.19. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.90.

OnKure Therapeutics's EPS (Diluted) for the three months ended in Mar. 2025 was $-1.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.90.

OnKure Therapeutics's EPS without NRI for the three months ended in Mar. 2025 was $-1.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -3.90.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

OnKure Therapeutics EPS (Basic) Historical Data

The historical data trend for OnKure Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics EPS (Basic) Chart

OnKure Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

EPS (Basic)

-2.21

-2.65

-15.28

OnKure Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial					-0.72	-1.06	-0.28	-1.37	-1.19

OnKure Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

OnKure Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-52.673	-	0)	/	3.447
	=	-15.28

OnKure Therapeutics's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-15.925	-	0)	/	13.424
	=	-1.19

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.90

OnKure Therapeutics (NAS:OKUR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

OnKure Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of OnKure Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

OnKure Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301

Website

https://www.onkuretherapeutics.com

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.